In vitro and in vivo activities of AM-112, a novel oxapenem

Jamieson, Conor E., Lambert, Peter A. and Simpson, Iain N. (2003). In vitro and in vivo activities of AM-112, a novel oxapenem. Antimicrobial Agents and Chemotherapy, 47 (5), pp. 1652-1657.


AM-112[1′R,5R,6R)-3-(4-amino-1,1-dimethyl-butyl)-6-(1′- hydroxyethyl)oxapenem-3-carboxylatel is a novel oxapenem compound which possesses potent β-lactamase-inhibitory properties. Fifty-percent inhibitory concentrations (IC50s) of AM-112 for class A enzymes were between 0.16 and 2.24 μM for three enzymes, compared to IC50s of 0.008 to 0.12 μM for clavulanic acid. Against class C and class D enzymes, however, the activity of AM-112 was between 1,000- and 100,000-fold greater than that of clavulanic acid. AM-112 had affinity for the penicillin-binding proteins (PBPs) of Escherichia coli DC0, with PBP2 being inhibited by the lowest concentration of AM-112 tested, 0.1 μg/ml. Ceftazidime was combined with AM-112 at 1:1 and 2:1 ratios in MIC determination studies against a panel of β-lactamase-producing organisms. These studies demonstrated that AM-112 was effective at protecting ceftazidime against extended-spectrum β-lactamase-producing strains and derepressed class C enzyme producers, reducing ceftazidime MICs by 16- and 2,048-fold. Similar results were obtained when AM-112 was combined with ceftriaxone, cefoperazone, or cefepime in a 1:2 ratio. Protection of ceftazidime with AM-112 was maintained against Enterobacter cloacae P99 and Klebsiella pneumoniae SHV-5 in a murine intraperitoneal sepsis model. The 50% effective dose of ceftazidime against E. cloacae P99 and K. pneumoniae SHV-5 was reduced from >100 and 160 mg/kg of body weight to 2 and 33.6 mg/kg, respectively, when it was combined with AM-112 at a 1:1 ratio. AM-112 demonstrates potential as a new β-lactamase inhibitor.

Publication DOI:
Divisions: Life & Health Sciences > Biosciences
Life & Health Sciences
Uncontrolled Keywords: AM-112 [(1′R,5R,6R)-3-(4-amino-1,1-dimethyl-butyl)-6-(1′-hydroxyethyl)oxapenem-3-carboxylate],oxapenem compound,β-lactamase-inhibitory properties,enzymes,clavulanic acid,ceftazidime,extended-spectrum β-lactamase-producing strains,β-lactamase inhibitor,Pharmacology (medical)
Full Text Link: http://aac.asm. ... tract/47/5/1652
Related URLs: http://www.scop ... tnerID=8YFLogxK (Scopus URL)
Published Date: 2003-05
Authors: Jamieson, Conor E.
Lambert, Peter A. ( 0000-0002-8243-2741)
Simpson, Iain N.

Export / Share Citation


Additional statistics for this record